Detection of recurrent transitional cell carcinoma of the bladder with nuclear matrix protein-22 in a follow-up setting

UroOncology

Volumn 2, Issue 3, 2002, Pages 137-142

  Oosterhuis, J W A ^a,d   Pauwels, R P E ^a   Schapers, R F M ^a   Van Pelt, J ^a   Smeets, W ^b   Newling, D W W ^c  

^a Stichting Ziekenhuizen Noord Limburg   (Netherlands)

^b Stichtig Klinische Genetica ZON   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d NONE   (Netherlands)

Author keywords

Bladder tumour; Follow up; Nuclear matrix; Recurrence; Transitional cell; Tumour markers

Indexed keywords

NUCLEAR MATRIX PROTEIN 22; NUCLEAR PROTEIN; PROTEIN; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER GRADING; CANCER SCREENING; CANCER STAGING; CELL NUCLEUS MATRIX; CYSTOSCOPY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECURRENT CANCER; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; TRANSITIONAL CELL CARCINOMA;

EID: 0036761813     PISSN: 15610950     EISSN: None     Source Type: Journal    
DOI: 10.1080/1561095021000040583     Document Type: Article

References (24)

1. Coebergh, J.W., Janssen, M., Louwman, M., Voogd, A., eds, (2001) Cancer Incidence, Car and Survival, 1995-1999: A Report of the Eindhoven Cancer Registry with Cross Border Implications (Comprehensive Cancer Centre South (IKZ), Eindhoven).
2. Lokeshwar, V.B. and Soloway, M.S. (2001) "Current bladder tumor tests: does their projected utility fulfill clinical necessity?", J. Urol. 165(4), 1067-1077.
3. Zippe, C., Pandrangi, L., Potts, J.M., Kursh, E., Novick, A. and Agarwal, A. (1999) "NMP22: A sensitive, cost-effective test in patients at risk for bladder cancer", Anticancer Res. 19(4A), 2621-2623.
4. Abel, P.D. (1997) "Follow-up of patients with superficial transitional-cell carcinoma of the bladder", In: Pagano, F. and Fair, W.R., eds, Superficial Bladder Cancer (Oxford University Press, Oxford), pp. 203-216.
5. Sharma, S., Zippe, C.D., Pandrangi, L., Nelson, D. and Agarwal, A. (1999) "Exclusion criteria enhance the specificity and positive predictive value of NMP22 and BTA stat", J. Urol. 162(1), 53-57.
6. Sanchez-Carbayo, M., Urrutia, M., Gonzalez de Buitrago, J.M. and Navajo, J.A. (2001) "Utility of serial urinary tumor markers to individualize intervals between cystoscopies in the monitoring of patients with bladder carcinoma", Cancer 92(11), 2820-2828.
7. Ponsky, L.E., Sharma, S., Pandrangi, L., Kedia, S., Nelson, D., Agarwal, A. and Zippe, C.D. (2001) "Screening and monitoring for bladder cancer: Refining the use of NMP22", J. Urol. 166(1), 75-78.
8. American Joint Committee on Cancer (AJCC), Beahrs, O.H., Henson, D.E., Hutter, R.V.P. and Kennedy, B.J. (1992) Manual for Staging of Cancer, 4th Ed. (J.B. Lippincott, Philadelphia).
9. Schapers, R.F., Pauwels, R.P., Wijnen, J.T., Arends, J.W., Thunnissen, F.B., Coebergh, J.W., Smeets, A.W. and Bosman, F.T. (1994) "A simplified grading method of transitional cell carcinoma of the urinary bladder: Reproducibility, clinical significance and comparison with other prognostic parameters", Br. J. Urol. 73(6), 625-631.
10. Chen, Y.T., Hayden, C.L., Marchand, K.J. and Makuch, R.W. (1997) "Comparison of urine collection methods for evaluating urinary nuclear matrix protein, NMP22, as a tumor marker", J. Urol. 158(5), 1899-1901.
11. Sackett, D.L., Straus, S.E., Richardson, W.S., Rosenberg, W.S. and Haynes, R.B. (2000) Evidence-Based Medicine. How to Practice and Teach EBM, 2nd Ed. (Churchill Livingstone, Edinburgh).
12. Giannopoulos, A., Manousakas, T., Mitropoulos, D., Botsoli-Stergious, E., Constantinides, C., Giannopoulou, M. and Choremi-Papadopoulou, H. (2000) "Comparative evaluation of the BTA stat test, NMP22, and voided urine cytology in the detection of primary and recurrent bladder tumors", Urology 55(6), 871-875.
13. Carpinito, G.A., Stadler, W.M., Briggman, J.V., Chodak, G.W., Church, P.A., Lamm, D.L., Lange, P., Messing, E., Pasciak, R.M., Reservitz, G.B., Ross, R.N., Rukstalis, D.B., Sarosdy, M.F., Soloway, M.S., Thiel, R.P., Vogelzang, N. and Hayden, C.L. (1996) "Urinary nuclear matrix protein as a marker for transitional cell carcinoma of the urinary tract", J. Urol. 156(4), 1280-1285.
14. Stampfer, D.S., Carpinito, G.A., Rodriguez-Villanueva, J., Willsey, L.W., Dinney, C.P., Grossman, H.B., Fritsche, H.A. and McDougal, W.S. (1998) "Evaluation of NMP22 in the detection of transitional cell carcinoma of the bladder", J. Urol. 159(2), 394-398.
15. Sanchez-Carbayo, M., Herrero, E., Megias, J., Mira, A. and Sofia, F. (1999) "Evaluation of nuclear matrix protein 22 as a tumour marker in the detection of transitional cell carcinoma of the bladder", BJU Int. 84(6), 706-713.
16. Menendez, V., Filella, X., Alcover, J.A., Molina, R., Mallafre, J.M., Ballesta, A.M. and Talbot-Wright, R. (2000) "Usefulness of urinary nuclear matrix protein 22 (NMP22) as a marker for transitional cell carcinoma of the bladder", Anticancer Res. 20(2B), 1169-1172.
17. Poulakis, V., Witzsch, U., De Vries, R., Altmansberger, H.M., Manyak, M.J., and Becht, E. (2001) "A comparison of urinary nuclear matrix protein-22 and bladder tumour antigen tests with voided urinary cytology in detecting and following bladder cancer: The prognostic value of false-positive results", BJU Int. 88(7), 692-701.
18. Fitzpatrick, J.M., West, A.B., Butler, M.R., Lane, V. and O'Flynn, J.D. (1986) "Superficial bladder tumors (stage pTa, grades 1 and 2): The importance of recurrence pattern following initial resection", J. Urol. 135(5), 920-922.
19. Oosterlinck, W., Kurth, K.H., Schroder, F., Bultinck, J., Hammond, B. and Sylvester, R. (1993) "A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder", J. Urol. 149(4), 749-752.
20. Oosterhuis, J.W.A., Schapers, R.F., Pauwels, R.P., Janssen, M., Newling, D.W.W. and ten Kate, F. (2002) "Histologic grading of papillary urothelial carcinoma of the bladder: Prognostic value of the 1998 WHO/ISUP classification system and comparison with conventional systems", J. Clin. Pathol. In press.
21. Serretta, V., Lo, P.D., Vasile, P., Gange, E., Esposito, E. and Menozzi, I. (1998) "Urinary NMP22 for the detection of recurrence after transurethral resection of transitional cell carcinoma of the bladder: experience on 137 patients", Urology 52(5), 793-796.
22. Kurth, K.H., Bouffioux, C., Sylvester, R., van der Meijden, A.P., Oosterlinck, W. and Brausi, M. (2000) "Treatment of superficial bladder tumors: achievements and needs. The EORTC Genito-urinary Group", Eur. Urol. 37(Suppl. 3), 1-9.
23. Hall, R.R., Parmar, M.K., Richards, A.B. and Smith, P.H. (1994) "Proposal for changes in cystoscopic follow up of patients with bladder cancer and adjuvant intravesical chemotherapy", BMJ 308(6923), 257-260.
24. Walsh, I.K., Keane, P.F., Ishak, L.M. and Flessland, K.A. (2001) "The BTA stat test: A tumor marker for the detection of upper tract transitional cell carcinoma", Urology 58(4), 532-535.